Anti-Complement C1S Antibody
- 产品详情
- 实验流程
Application
| WB, IHC, IF/IC |
|---|---|
| Primary Accession | P09871 |
| Reactivity | Human, Mouse |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 76684 Da |
| Gene ID | 716 |
|---|---|
| Other Names | Complement C1s subcomponent; C1 esterase; Complement component 1 subcomponent s |
| Target/Specificity | KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human Complement C1S. The exact sequence is proprietary. |
| Dilution | WB~~WB (1/500 - 1/1000) IHC~~1:100~500 IF/IC~~N/A |
| Format | Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. |
| Storage | Store at -20 °C.Stable for 12 months from date of receipt |
For Research Use Only. Not For Use In Diagnostic Procedures.
| Name | C1S {ECO:0000303|PubMed:3500856, ECO:0000312|HGNC:HGNC:1247} |
|---|---|
| Function | Component of the complement C1 complex, a multiprotein complex that initiates the classical pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:11445589, PubMed:16169853, PubMed:417728, PubMed:467643, PubMed:6271784, PubMed:6282646, PubMed:6319179, PubMed:70787, PubMed:9422791). C1S is activated following association of the C1 complex with immunoglobulins (IgG or IgM) complexed with antigens to form antigen-antibody complexes on the surface of pathogens (PubMed:34155115). C1S is cleaved and activated by C1R to generate C1s subcomponent heavy and light chains (PubMed:11445589, PubMed:6271784). C1s subcomponent light chain then cleaves and activates C2 and C4, the next components of the classical complement pathway (PubMed:16169853, PubMed:467643, PubMed:6282646, PubMed:6319179, PubMed:6906228, PubMed:70787, PubMed:9422791). |
| Cellular Location | Secreted. Cell surface. Note=Recruited to the surface of pathogens by the C1Q subcomplex. |
Research Areas
Application Protocols
Provided below are standard protocols that you may find useful for product applications.
REFERENCES
McKinnon C.M.,et al.Eur. J. Biochem. 169:547-553(1987).
Tosi M.,et al.Biochemistry 26:8516-8524(1987).
Kusumoto H.,et al.Proc. Natl. Acad. Sci. U.S.A. 85:7307-7311(1988).
Mural R.J.,et al.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
Endo Y.,et al.J. Immunol. 161:4924-4930(1998).
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
¥ 1,250.00
Cat# AP53288
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。